AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$GH

Talasaz AmirAli sold $6.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 37,500 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $169.16 ($168.20–$170.29, $6.34M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Aug 24, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for Guardant Health.

02

Market read

First public disclosure of a sizable insider sale by Guardant Health's co‑CEO.

03

What to watch

Potential upcoming clinical data releases may offset any negative sentiment from the sale.

Relevance 6/10Novelty 7/10Timing: filed 2026-08-24, reflects same‑day insider activity

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Co-CEO Talasaz AmirAli sold 37,500 shares for $6.34M via open-market transactions on 2026-08-21.

Expected impact

Potential slight dip in GH price over the next few days.

Evidence & confidence

Insider sales by a top executive can be viewed as a negative signal, but the amount ($6.3M) is not material for a mid‑cap biotech.

Market effects

Sector

Minimal impact on broader biotech sector; similar insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Company
    Guardant Health, Inc.

    Biotech firm focused on liquid biopsy diagnostics.

  • Executive
    Talasaz AmirAli

    Co-Chief Executive Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

SEP 15
$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

investing.com2 min
SEP 5
$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

simplywall.st2 min
SEP 4
$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

finance.yahoo.com2 min
AUG 25
$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.

pharmaphorum.com2 min